Yuhan

Yuhan EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Yuhan (000100.KS) as of Nov 22, 2026 is 70.93. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 138.92 — a change of -48.94% (lower).

EV/OCF

70.93

YoY

-48.94%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Yuhan is 2025 70.93 . EV/OCF (Enterprise Value to Operating Cash Flow) of Yuhan was 2024 138.92 . It decreases by -48.94% lower compared to the previous year.

The Yuhan EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
81.14 KRW
Jan 1, 2019
114.37 KRW
Jan 1, 2020
260.51 KRW
Jan 1, 2021
75.68 KRW
Jan 1, 2022
75.00 KRW
Jan 1, 2023
58.90 KRW
Jan 1, 2024
138.92 KRW
Jan 1, 2025
70.93 KRW
The Yuhan EV/OCF history
YEAREV/OCFYoY
70.93-48.94%
138.92+135.87%
58.90-21.47%
75.00-0.90%
75.68-70.95%
260.51+127.77%
114.37+40.97%
81.14+34.69%
60.24-41.70%
103.32+72.69%
59.83-24.69%
79.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Yuhan Stock analysis

What does Yuhan do? The Yuhan Corporation is a South Korean conglomerate that was founded on September 1, 1926, under the name "Chosun Pharmaceutical Company". The company is headquartered in Seoul and employs more than 5,000 people worldwide. History: The Yuhan Corporation started as a small company with a single product, a fish oil-based ointment called "Yuksundo". The company worked hard to improve its products and expand its market, eventually expanding into other business areas such as the production of antibiotics and diabetes treatments. In the early 1950s, the company also ventured into the research and development of other pharmaceuticals. In 1962, Yuhan became a publicly traded company and received a variety of awards in the following years, including several Korean Industrial Awards. Since its inception, the company has remained committed to improving people's lives through innovation and science. Business model: The Yuhan Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of drugs and other health products. The company also makes investments in innovative technologies and healthcare startups. Over the years, Yuhan has expanded its business through partnerships with other companies and acquisitions of companies such as LGL Holdings and SillaJen Inc. The company also engages in international business relations, such as selling its products and medications in other countries. Divisions: The Yuhan Corporation has four main business divisions: Medical Research and Development, Drug Manufacturing, Biotechnology Product Development, and Health Product Production. The first division is coordinated by Yuhan Research & Development Co. Ltd, while drug manufacturing is done by Yuhan Manufacturing Co. Ltd. Biotechnology is done by Yuhan Biomedical Research Institute, and the health product segment is handled by Yuhan Healthcare. Products: Yuhan's products are diverse and include a wide range of drugs and health products. The company is involved in the production of antibiotics, analgesics, vein treatment agents, diabetes medications, cardiovascular drugs, and other pharmaceutical products. Other products also include cosmetics, oral care products, and dermatology drugs. Some of Yuhan's well-known products include the antibiotic Ceclor, a medication for the treatment of diabetes and metabolic disorders, as well as apple-based cosmetic products. All Yuhan products are manufactured according to strict quality standards and are known for their effectiveness and safety. Conclusion: The Yuhan Corporation has evolved into a diverse and innovative company focused on the production of drugs and health products. The company has a long history with many successes and has established itself as one of the major forces in the South Korean economy over the past decades. Yuhan's mission to create better healthcare remains as relevant today as it was at the time of its founding. Yuhan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Yuhan stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Yuhan is 70.93 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Yuhan changed from 138.92 to 70.93, representing a -48.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Yuhan since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Yuhan with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Yuhan

All Key Metrics — Yuhan